IMMUNEERING CORP CLASS A (IMRX)
Health Care · Clinical-stage oncology / targeted cancer therapeutics · NASDAQ
Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of MEK/MAPK inhibitors designed to improve durability and tolerability in cancer by reducing toxicity and resistance through cadenced signaling inhibition.
What IMMUNEERING CORP CLASS A does
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors (DCI), a novel class of anti-cancer medicines designed to disrupt tumor cell proliferation while sparing healthy cells through cadenced signaling. The company's lead candidate, atebimetinib (IMM-1-104), is an oral MEK inhibitor in Phase 3 development for first-line pancreatic cancer in combination with modified gemcitabine/nab-paclitaxel, with a secondary program (envometinib) and preclinical research focused on MAPK and other core cancer signaling pathways.
Themes: MEK inhibitors / MAPK pathway, Targeted oncology, Pancreatic cancer, Non-small cell lung cancer, Precision medicine / translational bioinformatics, Resistance-overcoming therapeutics
Fundamentals
- Price$5.30 as of 2026-08-21 close
- Market cap$336M as of 2026-08-24
- 1-year return+14.5% 2025-08-21 close $4.63 → 2026-08-21 close $5.30
- P/En/a negative earnings
- Net margin-9610.0% as of 2026-08-24
- Gross margin+28.0% as of 2026-08-24
- ROE-27.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.33 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How IMRX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How IMMUNEERING CORP CLASS A looks technically
IMMUNEERING CORP CLASS A (IMRX) is trading 1.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 110 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 47.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.4% below its 200-day average, the long-term trend line — a long-term downtrend | -1.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.71 | $4.71 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.37 | $5.37 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 4.03. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 110 trading days ago — a "death cross", a bearish long-term signal | 110 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($4.20 to $5.43) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 89.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.08 | $10.08 |
|---|---|---|
| From the 52-week high | it is 47.4% below its 52-week high (its highest price of the past year) | -47.4% |
| Above the 52-week low | it is 63.1% above its 52-week low (its lowest price of the past year) | +63.1% |
| Below the 52-week high | it is 47.4% below its highest point of the past year | 47.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 51 trading days ago | 51 sessions |
| All-time high | its highest closing price on record is $33.67 (set on 2021-08-06) | $33.67 |
| Given back of the 52-week move | over the past year its closes ranged ($3.35 to $9.26), and it has given back well over two thirds of its rise from last year’s low — 67% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.42 to $5.61. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 67.0% |
| From the all-time high | it is 84.3% below its all-time high | -84.3% |
| Nearest price level | it is trading 0.8% above a support level at $5.26 — a price it turned at four times since 2025-10-22, most recently on 2026-04-15. Since 2024-08-21 it has 8 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | its lowest closing price on record is $1.00 (set on 2024-08-16) | $1.00 |
| Above the all-time low | it is 430.0% above its all-time low | +430.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 85% of the past ~6 months) | 85th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2551 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2551 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.81 and $5.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.81 – $4.69 – $5.56 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges below its 200-day average price (1.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.62× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.1% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 5.03 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 5.7% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.5 percentage points (the stock gained 18.8% while the market gained 2.3%) | +16.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.6 percentage points (the stock gained 1.5% while the market gained 3.1%) | -1.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.1 percentage points (the stock gained 6.0% while the market gained 11.1%) | -5.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 6.0 percentage points (the stock gained 14.5% while the market gained 20.5%) | -6.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 7.0% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.06 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +4.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.92 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +7.7% |
Price levels it has turned at before
IMRX last closed at $5.30 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.26 | Support | 0.8% below the last close | turned there four times · 2025-10-22 to 2026-04-15 |
| $4.82 | Support | 9.1% below the last close | turned there twice · 2026-03-06 to 2026-05-19 |
| $6.00 | Resistance | 13.2% above the last close | turned there twice · 2025-10-03 to 2025-11-07 |
| $4.04 | Support | 23.9% below the last close | turned there twice · 2026-01-13 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $4.03.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$18.25 range $12.00 – $30.00; median $17.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMRX
- Consensus EPS estimate-$0.3071 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Atebimetinib is in early Phase 3 development with no approved products; failure of the MAPKeeper 301 trial would jeopardize the lead program and company viability.","The company is unprofitable with a net margin of -9610% and has financed operations through debt and equity offerings; continued clinical development requires sustained funding.","DCI represents a novel mechanism of action; clinical and commercial validation is unproven, and competitive MEK/MAPK inhibitors from larger pharma may limit market adoption."]
What changed in the latest 10-Q
AI-assisted comparison of IMRX's 10-Q filed 2026-05-15 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing describes company as 'late-stage clinical oncology company' vs. older filing's 'clinical-stage oncology company'
- Newer filing includes reference to January 2026 announcement of positive interim response and safety data from Phase 2a trial
- Newer filing includes reference to April 2026 AACR annual meeting poster presentation on circulating tumor DNA data
- Newer filing states expectation to announce updated survival and safety data from expanded cohort of approximately 55 first-line pancreatic cancer patients in Q2 2026
- Newer filing states expectation to dose first patient in atebimetinib plus Libtayo trial in second half of 2026
- Newer filing references December 2022 as exclusive focus date vs. older filing's September 2022 IND clearance date
- Newer filing specifies MAPKeeper 301 as the name of the Phase 3 trial
- Newer filing provides specific Phase 3 design details: 320 mg once-daily dose, mGnP combination, primary endpoint of overall survival, secondary endpoints, planned enrollment of approximately 510 patients divided equally across two arms
- Newer filing references August 2025 Private Placement with specific terms: 5,251,349 common shares at $3.95, 1,077,764 Pre-Funded Warrants, 2,848,096 Purchase Warrants at $5.50 exercise price, and net proceeds of $23.4 million
- Newer filing references October 2025 Cashless Exercise of Pre-Funded Warrants
- Newer filing states no shares sold under 2022 ATM Program during three months ended March 31, 2026
- Newer filing states no shares sold under 2025 ATM Program during three months ended March 31, 2026 or March 31, 2025
- Removed:
- Older filing's reference to Annual Report on Form 10-K for fiscal year ended December 31, 2024 is replaced with December 31, 2025
- Older filing's reference to 'related financing' in forward-looking statements language is removed
- Older filing's description of company's development pipeline including 'a discovery program targeting RAS, an undisclosed target, and other small molecule drug discovery programs' is removed
- Older filing's reference to FDA clearing IND application in September 2022 and commencing Phase 1/2a dosing in November 2022 is not repeated in newer filing's overview section
- Older filing's reference to beginning Phase 2a cohorts in March 2024 is removed
- Older filing's detailed September 2025 interim data announcement (86% OS, 53% PFS, median PFS 9.6 months, 34 patients at 320 mg dose) is removed
- Older filing's reference to February 2025 clinical supply agreement with Regeneron for Libtayo is removed from newer filing's overview
- Older filing's reference to August 2025 clinical supply agreement with Eli Lilly for olomorasib is removed
- Older filing's discussion of Phase 1/2a trial design details and safety data specifics is removed
- Older filing's reference to envometinib (IMM-6-415) as 'second product candidate' with twice-daily dosing and December 2023 IND clearance is removed from newer filing's overview
- Reworded:
- Newer filing describes DCI mechanism as 'aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth' vs. older filing's 'aim to achieve durability by outpacing cancer, pulsing faster than cancer can adapt so tumors shrink slowly but durably'
- Newer filing states company is 'developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors' vs. older filing's 'aim to achieve this goal through Deep Cyclic Inhibitors'
- Newer filing describes atebimetinib design as 'designed to improve durability and tolerability across many cancer indications' vs. older filing's 'designed to improve durability and tolerability and expand indications beyond currently registered MEK inhibitors'
- Newer filing describes MEK inhibitors as 'chronically targeted precision therapies' vs. older filing's 'targeted therapies that are designed to chronically inhibit a signaling pathway 24/7'
- Newer filing references 'envometinib (IMM-6-415) and other pre-clinical research programs' vs. older filing's detailed description of IMM-6-415 as second product candidate in Phase 1/2a
- Newer filing states 'Phase 2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients, which is part of our ongoing Phase 1/2a clinical trial' vs. older filing's 'Phase 1/2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients'
- Notes:
- The older filing appears truncated at the end, cutting off mid-sentence regarding IMM-6-415 Phase 1/2a clinical trial details, which may affect completeness of removal assessment
- Comparison is between Q1 2026 filing (newer) and Q3 2025 filing (older), representing different reporting periods and potentially reflecting updated strategy or clinical progress
Risk Factors
- Added:
- Added language in first risk factor title: 'have not completed any registrational clinical trials' (newer filing, filed 2026-05-15)
- Added description of company stage: 'late-stage clinical oncology company' replacing 'clinical-stage oncology company' (newer filing, filed 2026-05-15)
- Added reference to 'MAPKeeper 301 registrational trial' with planned mid-2026 dosing (newer filing, filed 2026-05-15)
- Added financial data: net losses of approximately $13.5 million for three months ended March 31, 2026 and accumulated deficit of approximately $293.8 million as of March 31, 2026 (newer filing, filed 2026-05-15)
- Removed:
- Removed language specifying atebimetinib trial is 'in patients harboring RAS and/or RAF mutant tumors' from the ongoing Phase 1/2a clinical trial description (older filing, filed 2025-11-12)
- Removed reference to 'clinical trials' as something not yet completed; changed to 'registrational clinical trials' (older filing, filed 2025-11-12)
- Removed financial data: net losses of approximately $44.4 million for nine months ended September 30, 2025 and $61.0 million for year ended December 31, 2024, and accumulated deficit of approximately $268.7 million as of September 30, 2025 (older filing, filed 2025-11-12)
- Reworded:
- Changed 'clinical-stage oncology company' to 'late-stage clinical oncology company' throughout the risk factor (newer filing, filed 2026-05-15 vs older filing, filed 2025-11-12)
- Changed 'have not completed any clinical trials' to 'have not completed any registrational clinical trials' in the opening sentence (newer filing, filed 2026-05-15 vs older filing, filed 2025-11-12)
- Removed reference to patient population 'harboring RAS and/or RAF mutant tumors' from atebimetinib trial description in both the opening paragraph and the 'net losses' section (newer filing, filed 2026-05-15 vs older filing, filed 2025-11-12)
- Notes:
- The newer filing text appears truncated at the end ('achieve profi'); comparison is based on the available text
- Financial data and cumulative deficit figures are updated to reflect the most recent fiscal periods in each filing
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days2 buys ($35993) · 0 sells — 2 buying insiders
- Last 180 days2 buys ($35993) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-23. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IMRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,075,669
- Reported value $63,638,774
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IMRX had 15,401,519 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for IMRX because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 15,401,519
- Prior settlement (shares) 15,208,579
- Reported change 1.27%
- Days to cover (reported) 20.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Novartis (NVS)
- Roche (RHHBY)
- Eli Lilly (LLY)
- Pfizer (PFE)
- AstraZeneca (AZN)
- Revolution Medicines (RVMD)
- Mirati Therapeutics (MRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMRX vs…
Frequently asked questions
What does IMMUNEERING CORP CLASS A (IMRX) do?
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors (DCI), a novel class of anti-cancer medicines designed to disrupt tumor cell proliferation while sparing healthy cells through cadenced signaling. The company's lead candidate, atebimetinib (IMM-1-104), is an oral MEK inhibitor in Phase 3 development for first-line pancreatic cancer in combination with modified gemcitabine/nab-paclitaxel, with a secondary program (envometinib) and preclinical research…
What sector is IMMUNEERING CORP CLASS A (IMRX) in?
IMMUNEERING CORP CLASS A (IMRX) is classified in the Health Care sector. Its industry is Clinical-stage oncology / targeted cancer therapeutics. It trades on NASDAQ.
Who are IMMUNEERING CORP CLASS A's (IMRX) competitors?
Notable peers of IMMUNEERING CORP CLASS A (IMRX) include Amgen, Novartis, Roche, Eli Lilly and Pfizer. This peer set is informational only — not financial advice.
Is IMMUNEERING CORP CLASS A (IMRX) overbought or oversold right now?
IMMUNEERING CORP CLASS A (IMRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.